Skip to main content
. 2022 Aug 1;82(15):1477–1480. doi: 10.1002/pros.24423

Figure 1.

Figure 1

Cumulative sub‐hazard curve showing that patients with ≥2 years of gonadotrophin‐releasing hormone (GnRH) agonist use had significantly higher risk of the endpoint than those with <2 years of GnRH agonist use (sub‐hazard ratio 1.23 [1.04–1.46], p = 0.017). [Color figure can be viewed at wileyonlinelibrary.com]